Cargando…

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors

Capmatinib is a highly specific, potent and selective MET inhibitor. This was an open‐label, multicenter, dose‐escalation, phase I study conducted in Japanese patients with advanced solid tumors (not selected based on their MET status). The primary objective was to determine the maximum tolerated do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esaki, Taito, Hirai, Fumihiko, Makiyama, Akitaka, Seto, Takashi, Bando, Hideaki, Naito, Yoichi, Yoh, Kiyotaka, Ishihara, Kae, Kakizume, Tomoyuki, Natsume, Kazuto, Myers, Andrea, Doi, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447844/ https://www.ncbi.nlm.nih.gov/pubmed/30724423 http://dx.doi.org/10.1111/cas.13956

Ejemplares similares

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
por: Qin, Shukui, et al.
Publicado: (2019)

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Publicado: (2020)

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2019)

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
por: Brandes, Franziska, et al.
Publicado: (2015)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors
por: Esaki, Taito, et al.
Publicado: (2011)

INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models
por: Moran-Jones, Kim, et al.
Publicado: (2015)

Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study
por: Shiroyama, Mamiko, et al.
Publicado: (2023)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
por: Sun, Yige, et al.
Publicado: (2022)

Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer
por: Sandoval, Leticia, et al.
Publicado: (2023)

Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
por: Nakase, Hiroshi, et al.
Publicado: (2023)

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2019)

INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification
por: Sohn, Sung-Hwa, et al.
Publicado: (2019)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
por: Takahashi, Shunji, et al.
Publicado: (2016)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo, Matthew Z, et al.
Publicado: (2021)

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
por: Yoh, Kiyotaka, et al.
Publicado: (2016)

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018)

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
por: Tamura, Kenji, et al.
Publicado: (2016)

Team no. 280 SIN II
por: Thivent, Μ
Publicado: (1981)

ZNF280BY and ZNF280AY: autosome derived Y-chromosome gene families in Bovidae
por: Yang, Yang, et al.
Publicado: (2011)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
por: Kawakami, Hisato, et al.
Publicado: (2021)

Limited Inc
por: Derrida, Jacques
Publicado: (1988)

Trust Inc.
por: Yeomans, Matthew
Publicado: (2018)

Health Tract, No. 280: Passing Away
Publicado: (1867)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
por: Cravero, Paola, et al.
Publicado: (2020)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
por: Lefler, Daniel S, et al.
Publicado: (2022)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

HPLC with Fluorescence and Photodiode Array Detection for Quantifying Capmatinib in Biological Samples: Application to In Vivo and In Vitro Studies
por: Zayed, Aref, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects
por: Cui, Xiaoming, et al.
Publicado: (2022)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

Comparative analysis of KPC-2-encoding chimera plasmids with multi-replicon IncR:Inc(pA1763-KPC):IncN1 or IncFII(pHN7A8):Inc(pA1763-KPC):IncN1
por: Qu, Daofeng, et al.
Publicado: (2019)

ICM-AACR-INC
Publicado: (2009)

Inside Isis Inc
por: Financial Times
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1v1ss53266plffsd4l7ipqpr2n